Vitello Dominic J, Bentrem David J
Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
J Surg Oncol. 2021 May;123(6):1449-1459. doi: 10.1002/jso.26369.
Despite overall advances in cancer therapy, patients with pancreatic ductal adenocarcinoma continue to have a poor prognosis. While adjuvant therapy is still considered standard, there is mounting evidence that neoadjuvant therapy confers similar benefits in patients with locally advanced disease. The primary measures of response are radiographic, biochemical, margin status, and pathologic. Given overall low response rates and the need for new treatment strategies, standard metrics remain important to the investigation of new systemic agents.
尽管癌症治疗取得了整体进展，但胰腺导管腺癌患者的预后仍然很差。虽然辅助治疗仍被视为标准治疗方法，但越来越多的证据表明，新辅助治疗对局部晚期疾病患者具有类似的益处。反应的主要衡量标准是影像学、生化指标、切缘状态和病理情况。鉴于总体缓解率较低且需要新的治疗策略，标准指标对于新的全身治疗药物的研究仍然很重要。
